Boos J - Search Results

1

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.

Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G. Lanvers-Kaminsky C, et al. Among authors: boos j. Pharmacogenomics. 2015;16(4):323-32. doi: 10.2217/pgs.14.182. Pharmacogenomics. 2015. PMID: 25823781 Free PMC article.

2

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, am Zehnhoff-Dinnesen A. Riedemann L, et al. Among authors: boos j. Pharmacogenomics J. 2008 Feb;8(1):23-8. doi: 10.1038/sj.tpj.6500455. Epub 2007 Apr 24. Pharmacogenomics J. 2008. PMID: 17457342

3

Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.

Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J. Lanvers-Kaminsky C, et al. Among authors: boos j. Pediatr Blood Cancer. 2006 Aug;47(2):183-93. doi: 10.1002/pbc.20673. Pediatr Blood Cancer. 2006. PMID: 16302218

4

Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.

Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG. Lanvers-Kaminsky C, et al. Among authors: boos j. Clin Pharmacol Ther. 2014 Aug;96(2):156-7. doi: 10.1038/clpt.2014.67. Epub 2014 Mar 18. Clin Pharmacol Ther. 2014. PMID: 24642735 No abstract available.

5

Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.

Lanvers-Kaminsky C, Bremer A, Dirksen U, Jürgens H, Boos J. Lanvers-Kaminsky C, et al. Among authors: boos j. Anticancer Drugs. 2006 Jul;17(6):657-62. doi: 10.1097/01.cad.0000215059.93437.89. Anticancer Drugs. 2006. PMID: 16917211

6

Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.

Destanovic E, Boos J, Lanvers-Kaminsky C. Destanovic E, et al. Among authors: boos j. Anticancer Res. 2018 Jul;38(7):3977-3984. doi: 10.21873/anticanres.12684. Anticancer Res. 2018. PMID: 29970520

7

An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.

Spaniol K, Boos J, Lanvers-Kaminsky C. Spaniol K, et al. Among authors: boos j. Anticancer Drugs. 2011 Jul;22(6):531-42. doi: 10.1097/CAD.0b013e3283454526. Anticancer Drugs. 2011. PMID: 21637161

8

Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.

Arnhold V, Boos J, Lanvers-Kaminsky C. Arnhold V, et al. Among authors: boos j. Cancer Chemother Pharmacol. 2016 Mar;77(3):495-505. doi: 10.1007/s00280-016-2962-5. Epub 2016 Jan 19. Cancer Chemother Pharmacol. 2016. PMID: 26781311

9

In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.

Vorotnjak M, Boos J, Lanvers-Kaminsky C. Vorotnjak M, et al. Among authors: boos j. Anticancer Drugs. 2004 Sep;15(8):795-802. doi: 10.1097/00001813-200409000-00009. Anticancer Drugs. 2004. PMID: 15494642

10

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.

Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J, Lanvers-Kaminsky C. Heshe D, et al. Among authors: boos j. Cancer Chemother Pharmacol. 2011 Mar;67(3):647-55. doi: 10.1007/s00280-010-1361-6. Epub 2010 May 26. Cancer Chemother Pharmacol. 2011. PMID: 20502900

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters